Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

    November 2016 in “ Journal of the American Academy of Dermatology ”
    Brittany G. Craiglow, Lucy Liu
    Studysummary In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 8

    1. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    2. Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review Journal of The American Academy of Dermatology · 2016
    3. Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients Journal of the European Academy of Dermatology and Venereology · 2016
    4. Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers Experimental Dermatology · 2016
    5. Topical Ruxolitinib for the Treatment of Alopecia Universalis JAMA dermatology · 2015
    6. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    7. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    8. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014

    Related research 1

    1. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018